Novartis' JAK inhibitor Jakavi patient populations to come under NICE microscope
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, is to review Novartis/Incyte's orphan myelofibrosis treatment, Jakavi (ruxolitinib). The institute's draft appraisal scope, now out for consultation, indicates that the institute will be paying close attention to whether it can narrow the potential patient population.